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Background: Data are limited for mortality and comorbidities in patients with multiple sclerosis (MS).
Objectives: Compare mortality rates and event rates for comorbidities in MS (n¼15,684) and non-MS
(n¼78,420) cohorts from the US Department of Defense (DoD) database.
Methods: Comorbidities and all-cause mortality were assessed using the database. Causes of death
(CoDs) were assessed through linkage with the National Death Index. Cohorts were compared using
mortality (MRR) and event (ERR) rate ratios.
Results: All-cause mortality was 2.9-fold higher in the MS versus non-MS cohort (MRR, 95% confidence
interval [CI]: 2.9, 2.7–3.2). Frequent CoDs in the MS versus non-MS cohort were infectious diseases
(6.2, 4.2–9.4), diseases of the nervous (5.8, 3.7–9.0), respiratory (5.0, 3.9–6.4) and circulatory (2.1, 1.7–2.7)
systems and suicide (2.6, 1.3–5.2). Comorbidities including sepsis (ERR, 95% CI: 5.7, 5.1–6.3), ischemic
stroke (3.8, 3.5–4.2), attempted suicide (2.4, 1.3–4.5) and ulcerative colitis (2.0, 1.7–2.3), were higher in
the MS versus non-MS cohort. The rate of cancers was also higher in the MS versus the non-MS cohort,
including lymphoproliferative disorders (2.2, 1.9–2.6) and melanoma (1.7, 1.4–2.0).
Conclusions: Rates of mortality and several comorbidities are higher in the MS versus non-MS cohort.
Early recognition and management of comorbidities may reduce premature mortality and improve
quality of life in patients with MS.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
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Fig. 1. Attrition of the MS cohort. MS, multiple sclerosis.
G. Capkun et al. / Multiple Sclerosis and Related Disorders 4 (2015) 546–554 547et al., 2010) and comorbidities such as infection-related hospital
admissions (Montgomery et al., 2013), cardiovascular disease
(CVD) (Christiansen et al., 2010; Jadidi et al., 2013) and other au-
toimmune conditions (Berkovich et al., 2011; Christiansen, 2012;
Marrosu et al., 2002), while studies assessing the risk of cancer in
patients with MS have been inconclusive (Bloomgren et al., 2012;
Handel and Ramagopalan, 2010; Kingwell et al., 2012a). The au-
toimmune pathogenesis of MS may contribute to the predisposi-
tion to certain comorbidities, including type 1 diabetes and in-
flammatory bowel diseases (Berkovich et al., 2011). However, so-
cioeconomic status, reduced levels of physical activity and im-
munomodulatory treatment may also affect the risk of premature
mortality and comorbidities (Eyre et al., 2004).
Differences in mortality rates (MRs), causes of death (CoDs) and
comorbidity event rates (ERs) in individuals with MS and those
without MS have not been fully investigated. Such data may have
important implications for the management of patients with MS,
particularly if the risk of comorbidities can be reduced by focused
surveillance, which may permit early detection or diagnosis, and
targeted intervention. Furthermore, establishing baseline ex-
pectations of mortality and comorbidity rates in patients with MS
can provide a reference against which the relative safety profiles of
disease-modifying therapies (DMTs) can be assessed. Therefore,
this study is an administrative claims database analysis comparing
MRs, CoDs and ERs for comorbidities in a cohort of patients with
MS versus a matched cohort of individuals without MS, using the
US Department of Defense (DoD) Military Health System database.2. Materials and methods
The DoD database contains information on over 10 million active
US military personnel, their dependents, and retirees, and includes
information on patient demographics, enrollment, healthcare provi-
ders, diagnoses, procedures and prescriptions (Dorrance et al., 2013).
The DoD database also contains mortality data, and through linkage
with the US National Death Index (NDI), CoDs can be identified. De-
mographics of the DoD database population relative to the US general
population are summarized in Supplementary Fig. 1 and Supple-
mentary Table 1. Characteristics of the DoD database are further de-
scribed by Dorrance et al. (2013).
Individuals aged 18–64 years were selected from the DoD da-
tabase between 1 July 2006 and 30 June 2011. An algorithm
(Chastek et al., 2010), appropriate for use in administrative claims
databases (Song et al., 2013), was applied to the DoD database to
identify patients with MS, for whom diagnosis codes for MS (In-
ternational Classification of Diseases [ICD] 9 Clinical Modification
[CM] 340.xx) appeared on two or more occasions at least 30 days
apart (Chastek et al., 2010). Patients were excluded from the MS
cohort if they did not meet the inclusion criteria (Fig. 1). The index
date for patients in the MS cohort was the date of the second entry
of the MS diagnosis code in their healthcare records (Suissa, 2008).
To enable assessment of medical history, only individuals with at
least 1 year of pre-index enrollment were included. The MS cohort
comprised treated and untreated patients with incident (newly
diagnosed after entry into the DoD healthcare system) and pre-
valent (diagnosed before entry into the DoD healthcare system)
MS. From the same time period, five individuals with no MS claims
in their healthcare records and at least 1 year of pre-index en-
rollment, were matched to each patient with MS by age (within
5 years), gender and index date to create the non-MS cohort. In-
dividuals aged Z65 years on the index date, who may also have
concurrent access to Medicare coverage, were excluded from the
study due to the risk of incomplete follow-up information if
treatments were reimbursed via Medicare (Social Security Ad-
ministration, 2014).To include all medical encounters during the study period, in-
dividuals in both cohorts were followed from their index date until
the date that they ceased receiving DoD healthcare benefits, their
death or the end of the study period; patients were not censored if
they turned 65 years of age during the follow-up period.
Individuals with the occurrence of a clinical event in the fol-
low-up period were subsequently censored for reoccurrences of
that event but continued to be assessed for the occurrence of other
comorbidities. Death of an individual was identified through the
registration date of their death in the NDI. To determine CoD,
ICD-10-CM codes on the death certificate were ordered, listing the
immediate CoD (final disease or condition resulting in death), any
secondary CoDs and the primary underlying CoD (the disease or
injury that initiated the events leading to death) (Goodin et al.,
2014). The cause most directly leading to death (CLD) was con-
sidered as the main CoD analysis in this study because it may be
more meaningful in patients with MS than immediate and primary
underlying CoDs, and allows for designation of suicide (Goodwin
et al., 2014). We used a definition similar to that of Goodwin et al.
(2014) assess CLD, which was the ICD-10-CM code closest to the
time of death, with the following exceptions: suicide was the CLD
if it appeared anywhere on the death certificate; MS was the CLD
only if no cause other than cardiac or respiratory arrest was given
or MS was the only code mentioned; cardiac or respiratory arrest
were designated as the CLD only if those causes and no others
were provided on the death certificate. Over 200 comorbidities
were assessed using ICD-9-CM codes. Comorbidities among a
subgroup of patients in the MS cohort who had one or more claims
for DMTs (fingolimod, natalizumab, glatiramer acetate, interferon
beta-1a, interferon beta-1b or mitoxantrone), at any time during
the study (treated MS cohort) were also compared with those in a
matched non-MS cohort. In this study, the prevalence of co-
morbidities in the post-index period was assessed and ERs re-
ferred to both acute and chronic conditions. The distributions of
mortality and event rate ratios (MRRs and ERRs) were also as-
sessed according to gender and age.
Differences between the MS and non-MS cohorts in terms of
pre-index characteristics were assessed using a t-test for con-
tinuous variables and a Wilcoxon rank-sum test, a χ2 test or a
Fisher’s exact test for categorical variables. MRs and ERs for
G. Capkun et al. / Multiple Sclerosis and Related Disorders 4 (2015) 546–554548comorbidities were calculated for each cohort and used to derive
MRRs and ERRs with 95% confidence intervals (CIs; Table 1). Rate
ratios were reported because they are more likely to be in-
dependent of population- and database-specific biases compared
with MRs and ERs and are therefore more generalizable.3. Results
3.1. Study attrition and cohort characteristics
Initially, 31,597 patients with an MS diagnosis were identified
in the database. After applying the study selection criteria, the fi-
nal MS (Fig. 1) and non-MS cohorts included 15,684 and 78,420
individuals, respectively.
Demographic and clinical characteristics for each cohort are
summarized in Table 2. Owing to matching, the mean age of in-
dividuals (46.0711.7 years) and the proportion of women (76.5%)
were similar in both cohorts. The mean duration of follow-up was
significantly longer in the MS cohort (15187638 days) than in the
non-MS cohort (14147716 days; po0.0001).
3.2. Mortality and CoD
For all-cause mortality, the MRR was 2.9 (95% CI, 2.7–3.2;Fig. 2. Forest plots of crude MRRs for all-cause mortality and selected causes leading to
confidence interval; MR, mortality rate; MRR, mortality rate ratio; MS, multiple sclerosis
suicide.
Table 1
Statistical analyses used to assess mortality rates and event rates for comorbidities.
Methodology
Mortality rate (for all-cause and
specific causes of death)
Calculated by dividing the number of patients wh
follow-up, or died from a specific cause, by the su
son-time during follow-up for each cohort; perso
fined as the number of days from the index date
death or the end of the follow-up
Mortality rate ratio (for all-cause
and specific causes of death)
Dividing the mortality rate in the MS cohort by th
MS cohort
Event rate for each comorbidity of
interest
Calculated by dividing the number of patients wit
during follow-up by the person-time at risk for th
each cohort (censored by first event occurrence)
Event rate ratio for each co-
morbidity of interest
Dividing the event rate in the MS cohort by that
cohort
CI, confidence interval; MS, multiple sclerosisFig. 2) and was highest among individuals aged 18–29 years
(MRR, 95% CI: 8.8, 3.7–21.0).
For the CLD, the MRR was highest for infectious diseases
(6.2, 4.2–9.4; Fig. 2) and ratios were higher among those aged
50–59 years (9.4, 5.3–16.7) than in any other age group. Following
infectious diseases as the CLD, MRRs were high for diseases of the
nervous system (5.8, 3.7–9.0; excluding MS), respiratory system
(5.0, 3.9–6.4; excluding respiratory arrest) and circulatory system
(2.1, 1.7–2.7; excluding cardiac arrest). For diseases of the nervous
system as the CLD, MRRs were higher in men than in women
(11.9, 4.2–33.3 versus 4.7, 2.8–7.9). The MRR for suicide was 2.6
(1.3–5.2) and was higher in women than in men (3.4, 1.4–8.5
versus 1.7, 0.5–5.2) and highest among those aged 18–29 years
(10.1, 1.1–97.4). A full list of CLDs is presented in Supplementary
Table 2. MS was the leading contributor to immediate and primary
underlying CoDs in the MS cohort versus the non-MS cohort (Ta-
ble 3). Following MS, MRRs were highest for infectious diseases
and diseases of the respiratory system (excluding respiratory ar-
rest) for the immediate CoD and diseases of the nervous system
(excluding MS) and infectious diseases for the primary underlying
CoD.
3.3. Prevalent comorbidities
The ERs and ERRs for comorbidities are presented in Fig. 3 and
Supplementary Table 3 and data for those comorbiditiesdeath in the MS cohort versus the non-MS cohort. Error bars indicate 95% CIs. CI,
. aexcluding MS; bexcluding cardiac arrest; cexcluding respiratory arrest; dexcluding
Analysis
o died during
m of the per-
n-time is de-
to the date of
Presented as number of patients with that outcome per 1000
patient-years with 95% CIs
at in the non- Presented with 95% CIs calculated using a binomial distribution;
a number greater than one indicates an increased rate of all-
cause mortality or death from a specific cause in the MS cohort
versus the non-MS cohort
h the outcome
at outcome in
Presented as number of patients with that outcome per 1000
patient-years with 95% CIs
in the non-MS Presented with 95% CIs calculated using a binomial distribution;
a number greater than one indicates an increased rate of a co-
morbidity in the MS cohort versus the non-MS cohort
Table 2






Age at index date, years
Mean7SD 46.0711.7 46.0711.7 0.81
Median (range) 47 (18–64) 47 (18–64)
Female, n (%) 11,992 (76.5) 59,960 (76.5)
Use of ambulatory aids,c n (%)
No claims for ambulatory aids 13,503 (86.1) 76,622 (97.7) o0.0001
Walks with assistance 789 (5.0) 1356 (1.7)
Cannot walk with assistance 1233 (7.9) 423 (0.5)
Restricted to bed 159 (1.0) 19 (0.02)
Duration of follow-up, days
Mean7SD 1517.77637.5 1413.47716.4 o0.0001
Median (range) 1733 (2–2191) 1616 (1–2191)
Pre-index drugs that can be used in the treatment of MS,d
n (%)
Systemic corticosteroidse 5114 (32.6) 9992 (12.7) o0.0001
Interferon beta-1a 3591 (22.9) 2 (0.002)
Glatiramer acetate 2242 (14.3) 0 (0.0)
Interferon beta-1b 1148 (7.3) 0 (0.0)
Methotrexatee 184 (1.2) 311 (0.4) o0.0001
Azathioprinee 77 (0.5) 81 (0.1) o0.0001
Natalizumab 70 (0.4) 0 (0.0) o0.0001
Cyclophosphamidee 30 (0.2) 71 (0.09) 0.0004
Fingolimod 8 (0.05) 0 (0.0) o0.0001
Mitoxantrone 4 (0.03) 0 (0.0) 0.0008
MS, multiple sclerosis; SD, standard deviation.
a The index date is defined as the date of the second MS diagnosis following at least 1 year of continuous enrollment.
b P-values from t-test for continuous variables, chi-square or Fisher's exact test for nominal categorical variables, and Wilcoxon rank sum for ordinal categorical
variables.
c Disease severity defined during the 1-year pre-index period and up to 1 year post index.
d Drug utilization identified any time during the pre-index period. The total numbers may not be the same as the number of patients receiving treatment because some
may have received multiple drugs.
e These drugs are not specifically indicated for MS and can be used to treat other conditions.
Table 3
Causes of death in the MS and non-MS cohort.a
Cause leading to death Primary underlying cause of death Immediate cause of death
Mortality rate
ratio
95% CI Mortality rate
ratio




Cardiac/respiratory arrest 2.30 0.58–9.20 1.85 0.58–5.89 3.62 2.76–4.77
Suicide 2.56 1.26–5.16 2.56 1.26–5.16 NA NA
Other causes of death (by ICD-10 category)c
Certain infectious and parasitic diseases 6.24 4.17–9.36 3.50 1.99–6.16 5.77 3.65–9.13
Neoplasms 1.24 0.97–1.57 1.20 0.96–1.49 1.27 0.99–1.64
Diseases of the nervous system (excluding MS) 5.75 3.66–9.04 6.45 3.68–11.31 2.92 1.67–5.11
Diseases of the circulatory system (excluding cardiac arrest) 2.12 1.68–2.66 1.74 1.36–2.24 1.91 1.48–2.47
Diseases of the respiratory system (excluding respiratory arrest) 4.99 3.86–6.44 2.20 1.47–3.29 4.80 3.64–6.32
Injury, poisoning and certain other consequences of external
causes (excluding suicide)
1.52 0.87–2.68 NA NA 1.92 1.23–2.97
CI, confidence interval; CoD, cause of death; ICD-10, International Classification of Diseases 10th revision; MRR, mortality rate ratios; MS, multiple sclerosis; NA, not
applicable.
a Of those who died, cause of death data was available for 89.6% of individuals in the MS cohort and 86.6% of individuals in the non-MS cohort. Cause of death data was
not available for all patients due to the 2-year delay in NDI reporting.
b For MS as a CoD the MRR outcome for each CoD category was NA.
c A full list of the conditions in each CoD category is provided in the World Health Organization International Statistical Classification of Diseases and Related Health
Problems 10th Revision (World Health Organization, 2010).
G. Capkun et al. / Multiple Sclerosis and Related Disorders 4 (2015) 546–554 549demonstrating an age- or gender-related difference are presented
in Supplementary Fig. 2.
The rate of all evaluated malignancies was higher in the MS cohortversus the non-MS cohort and varied by cancer type, being highest for
lymphoproliferative disorders (ERR, 95% CI: 2.2, 1.9–2.6) and mela-
noma (1.7, 1.4–2.0; Fig. 3a). For melanoma, ERRs were higher in
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in those aged 18–29 years (4.0, 1.3–11.9; Supplementary Fig. 2a). For
breast cancer in women, the highest ERRs were reported for those
aged 30–39 years (2.1, 1.3–3.3; Supplementary Fig. 2b).
Other systemic diseases (including autoimmune disorders) such as
ulcerative colitis (2.0, 1.7–2.3), regional enteritis (1.9, 1.6–2.3) and
thyroid gland disorders (1.5, 1.5–1.6) were more common in the MS
cohort than in the non-MS cohort (Fig. 3b). For diabetes mellitus, ERRs
decreased with increasing age (Supplementary Fig. 2c).
For cardiovascular comorbidities, vascular disorders of the cen-
tral nervous system (CNS) were more common in the MS cohort
than in the non-MS cohort (3.6, 3.5–3.8), with the highest ERR
being for ischemic stroke (3.8, 3.5–4.2; Fig. 3c). For myocardial in-
farction, the ERR was 2.1 (1.9–2.3; Fig. 3c) and the ratio was higher
in women than in men (2.3, 2.0–2.6 versus 1.6, 1.4–1.9; Supple-
mentary Fig. 2e). ERRs for cardiovascular comorbidities generally
decreased with increasing age (Supplementary Fig. 2d–g).
For infections, the highest ERRs were for sepsis (5.7, 5.1–6.3),
opportunistic infections (3.1, 2.9–3.2) and urinary tract infections
(UTIs; 2.2, 2.2–2.3; Fig. 3d). ERRs for infections decreased with
increasing age, with the exception of UTIs which increased with
age. ERRs were higher in men than in women for UTIs (3.0, 2.8–3.3
versus 2.2, 2.1–2.3; Supplementary Fig. 2h) and for sepsis
(7.5, 6.1–9.2 versus 5.1, 4.6–5.8; Supplementary Fig. 2i).
The ERR for attempted suicide was 2.4 (1.3–4.5), which is very
similar to the MRR for suicide as a CLD (2.6, 1.3–5.2). For all depres-
sion, the ERR was 2.8 (2.7–2.9; Fig. 3e) and was higher in men than in
women (4.1, 3.9–4.4 versus 2.7, 2.6–2.8; Supplementary Fig. 2j).
The results thus far given are for the entire MS cohort, of which
60.4% of patients had received DMTs in the past. In general, ERRs
for the DMT treated MS subcohort (Fig. 3, gray data points) were
similar to those for the full MS cohort (Fig. 3, black data points),
with the exception of slightly lower ERRs for diabetes mellitus,
coronary artery disorders, respiratory infections and UTIs in the
treated MS subcohort versus the full MS cohort.4. Discussion
This study, utilizing the US DoD database, provides a compre-
hensive analysis of mortality and more than 200 comorbidities in
patients with MS. This analysis showed that rates of mortality and
comorbidities were generally higher in the MS cohort than in the
matched non-MS cohort. The higher rate of all-cause mortality
(MRR, 95% CI: 2.9, 2.7–3.2) in the MS cohort versus the non-MS
cohort is within the range previously reported (1.7–3.5-fold) (Jick
et al., 2014; Kaufman et al., 2014; Kingwell et al., 2012b; Lalmo-
hamed et al., 2012; Rodriguez-Antiguedad Zarranz et al., 2014). In
CLD analyses, patients with MS had significantly higher rates of
death caused by infections (6.2, 4.2–9.4) than the matched non-MS
cohort. In addition, rates of death caused by diseases of the nervous
system (5.8, 3.7–9.0; excluding MS), respiratory systemFig. 3. Forest plots of crude ERRs for (a) malignancies, (b) autoimmune disorders, (c) cardiovascul
treated MS (gray data points) cohorts versus the non-MS cohort. Error bars indicate 95% CI. CI, c
multiple sclerosis. aLymphoproliferative disorders comprised lymphomas, leukemia andmultiplem
other nervous system organs, colon and rectum, lung and bronchus, cervix uteri, corpus uteri, ov
malignant neoplasms. cThe ‘Other systemic diseases’ category includes autoimmune disorders. dA
goiter, thyrotoxicosis with or without goiter, acquired hypothyroidism, thyroiditis, other disorder
pregnancy, childbirth or the puerperium, tuberculosis of the thyroid gland, endocrine exophthalm
granulosus infection of the thyroid, non-specific abnormal results of function of the thyroid. Con
included cardiac conduction disorder, ventricular fibrillation/flutter, ventricular tachycardia and
morrhagic stroke, other stroke and transient cerebrovascular disease/accident. gAll coronary art
coronary artery embolism/thrombosis, ischemic coronary artery disorder and ischemic heart disea
iAll herpes virus infections comprised chicken pox, herpes zoster, herpes simplex and other hum
poisoning by gases in domestic use, poisoning by other gases and vapors, hanging, strangulation a
piercing instruments, injury by jumping from high places, injury by other and unspecified mean(5.0, 3.9–6.4; excluding respiratory arrest) and circulatory system
(2.1, 1.7–2.7; excluding cardiac arrest) were also higher for the MS
cohort versus the non-MS cohort; for circulatory system diseases,
rates were unexpectedly high and it may be because of the inclu-
sion of multiple comorbidities within this category (World Health
Organization, 2010). These MRRs are higher than those of Goodin
et al. (2014) but are in agreement with their finding that infections
(3.4-fold higher), CVD (1.5-fold higher) and pulmonary disorders
(2.5-fold higher) were the most frequent CLDs in individuals with
MS compared with those without MS (Goodwin et al., 2014).
Therefore, the present study validates the findings of Goodin et al.
(2014), which was performed in a different population.
Consistent with other reports on comorbidities in patients with
MS, this study found that infections, CVDs, other systemic diseases
(including autoimmune disorders) and psychiatric disorders were
more common in the MS cohort than in the non-MS cohort (Ber-
kovich et al., 2011; Christiansen, 2012; Marrie et al., 2014; Marrosu
et al., 2002; Montgomery et al., 2013; Patten et al., 2003). For some
conditions, there were age- and gender-related differences in the
ERRs. In particular, the influence of MS on the risk of CVDs was
especially important in younger patients. Gender-related differ-
ences in comorbidities were generally maintained across most age
groups (data not shown). In contrast to results reported from
registry studies, which described a reduced risk of cancer (Bah-
manyar et al., 2009; Kingwell et al., 2012a; Lebrun et al., 2008;
Nielsen et al., 2006), we observed higher rates of all evaluated
malignancies in the MS cohort versus the non-MS cohort. Differ-
ences in observations between this study and registry studies may
reflect differences in cohort selection criteria, patient populations,
levels of data availability from claims databases versus registries,
sample sizes and follow-up time, as well as variations in data re-
cording and collection methods. Differences in study design
complicate the comparisons that can be made between this study
and others, as well as the conclusions that can be drawn (Marrie
et al., 2015b). Further studies are therefore warranted to fully ex-
plore the complex relationship between MS and cancer. This study
focused on individuals aged 18–64 years, which is the age range
generally included in clinical trials. By excluding patients aged
Z65 years, who are likely to have an increased rate of certain
comorbidities, regardless of whether they have MS, this study is
likely to be more informative to clinicians as ERRs and MRRs
would not be diminished by the effect of increased age.
This study emphasizes that the medical issues faced by in-
dividuals with MS are not limited to MS, but include an increased
frequency of certain comorbidities, which may contribute to a
higher risk of premature mortality. Therefore, by reporting the
increased risk of comorbidities and premature mortality in the MS
population, this study encourages the enhanced medical surveil-
lance of patients with MS to identify those at risk so that MS-
treating clinicians can recommend protective lifestyles and colla-
borate closely with general medical professionals to achieve ear-
lier diagnoses and therapy. This could prevent and/or reduce thear diseases, (d) infections and (e) psychiatric disorders in the full MS (black data points) and
onfidence interval; CNS, central nervous system; ER, event rate; ERR, event rate ratio; MS,
yeloma exceptmyelodysplastic syndromes. bAll additional cancer sites comprised brain and
ary, stomach, liver, pancreas, kidney, urinary/bladder, esophagus, thyroid and all solid organ
ll disorders of the thyroid gland included simple and unspecified goiter, non-toxic nodular
s of the thyroid, benign neoplasm of the thyroid glands, thyroid dysfunction complicating
os, openwound of the thyroid glandwith or withoutmention of complication, echinococcus
genital hypothyroidism and parathyroid disorders were excluded. eAll cardiac arrhythmias
cardiac arrest. fAll central nervous system vascular disorders included ischemic stroke, he-
ery disorders included angina pectoris, acute myocardial infarction, myocardial infarction,
se. hAll opportunistic infections comprised parasite, fungal, mycobacterial and viral infections.
an herpes viruses. jAll attempted suicide comprised poisoning by solid or liquid substances,
nd suffocation, submersion, injury by firearms, air guns and explosives, injury by cutting and
s and late effects of self-inflicted injury.
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and prolong the survival of patients with MS. While some co-
morbidities could be linked to the pathogenesis of MS (Chris-
tiansen, 2012; Jadidi et al., 2013; Kingwell et al., 2012a), other
significant contributors may include lower socioeconomic status
(Marrie et al., 2014), smoking, obesity, alcohol consumption and
the consequences of reduced physical activity as a result of MS-
induced physical impairment. However, the contributions of these
other factors are beyond the scope of the present study.
Post-approval observational studies have provided valuable in-
formation on the safety profiles of MS treatments (Holmen et al.,
2011; Ontaneda et al., 2012), but have not considered the possibility
that adverse events may be linked to the underlying increased risk
of certain comorbidities in patients with MS rather than solely due
to DMTs. In the present study, ERRs for the subcohort of patients
with MS who had received DMTs at any time during the study were
similar to ERRs for the full MS cohort versus the matched non-MS
cohort. ERRs were not calculated for the untreated MS subcohort
versus the treated MS subcohort because of the potential con-
siderable measurable and non-measurable differences between
these populations, including differences in disease severity, time
since diagnosis and age, which make subcohort matching difficult.
Generally, our data provide insights into comorbidities associated
with patients with MS in current clinical practice, which could be
used to compare the safety profiles of new DMTs. We suggest that
further studies are carried out to investigate the influence of DMTs
on the comorbid profile of patients with MS, by carrying out ana-
lyses combining claims data and registry data.
Although the DoD database is smaller than some other US
claims databases, a strength of this study is that it comprises in-
formation from a large, single-payer, lifetime healthcare system
and contains high-quality data for individuals with and without
MS, including their comorbidities and all their medications cov-
ered by the healthcare system. Thus, the clinical course of MS can
be investigated and compared against a non-MS cohort selected
from the same dataset. Approximately 60% of encounters recorded
in the database occur in civilian facilities, which are recorded as
administrative claims data. The remaining 40% occur in military
facilities and include information from electronic medical records
(EMRs) in addition to claims information. To maximize the sample
size and generalizability, claims-level information from both set-
tings was used for the analyses presented here. In future analyses,
EMR-level data could provide greater insight into the cohorts
being investigated. Furthermore, in contrast to other adminis-
trative claims databases, the DoD database collects mortality data
for the entire database population, facilitating the study of all-
cause mortality and CoDs, through linkage with the NDI. Owing to
the 2-year delay in NDI reporting, it was not possible to determine
the CLD for 10% and 13% of individuals in the MS and non-MS
cohorts, respectively.
A limitation of this study is that there may be significant de-
mographic differences between the DoD database population and
the general US population, such as the racial/ethnic composition,
socioeconomic and educational status (Stewart, 2005), although
there is evidence to suggest that these populations are comparable
in terms of overall disease profiles (Dorrance et al., 2013). A similar
analysis of comorbidities in the US MarketScan Research adminis-
trative claims database, which contains data on a population re-
garded as being broadly representative of the commercially insured
US population (Truven Health Analytics, 2012) provided similar ERR
results (Capkun et al., 2014). A general limitation of claims data-
bases, including the DoD database, is the short follow-up duration,
although the length of follow-up in this study was longer than that
of many other claims databases and clinical trials. While shorter
follow-up data may limit assessment of mortality, comorbidity re-
sults may be more meaningful in the short-term as longer timeframes are associated with increased patient drop-out. The follow-
up time in the MS cohort was 7% longer than that in the non-MS
cohort; this small but significant difference may have led to some
bias in the ERRs. However, overall, any bias arising from the follow-
up duration is unlikely to diminish the impact of the results.
There is also a possibility of over-reporting comorbidity events
identified through claims because diagnosis codes also serve as
billing codes to justify medical services. Surveillance bias arising
frommore attentive and cautious medical management of patients
with MS may lead to greater opportunities for recording billing
codes and otherwise non-reported comorbidities and may par-
tially account for the increased frequency observed for some co-
morbidities (e.g. infections) in the MS cohort versus the non-MS
cohort (Montgomery et al., 2013). However, major events (e.g.
myocardial infarction) are unlikely to be missed in either cohort
and would therefore not be subject to surveillance bias. To limit
bias when assessing comorbidities, relative ERs were assessed
(ERRs) rather than comparing absolute ERs.
In this study, comorbidities were identified from a single claim,
and did not use a second claim to provide confirmation of events,
which may bias results (Marrie et al., 2015a). However, using
lymphoma as an example, we have demonstrated that increasing
the number of claims (from one claim to two) did not substantially
alter the significance of the findings (data on file). However, the
impact of the number of claims used to identify comorbidities
from administrative claims databases may vary across diseases. For
individuals in the MS cohort, two ICD-9-CM claims for MS were
required; claims for DMTs were not included as an additional
criterion for inclusion in the MS cohort, owing to the fact that not
all patients with MS receive DMTs. While this may have led to
some misclassification of individuals without MS into the MS co-
hort, this is unlikely to have had a significant impact on the results.
Owing to the absence of specific codes for the onset of certain
comorbidities, and the limited medical history information (re-
quirement of at least 1-year pre-index enrollment), it was not
possible to accurately estimate the onset of MS or the incidence
rates of comorbidities (new onset events first occurring during
follow-up) in this study. In addition, although data on congenital
disorders and pregnancy conditions were available, these analyses
would require a different study design from that used to assess the
other comorbidities and were therefore not included here. Finally,
other than adjusting for age and gender, these analyses did not
control for other cohort differences, such as lifestyle changes and
disease severity, because data were not available.
4.1. Conclusions
Using high-quality data from the DoD database, this study
provides insights into the long-term health profile of patients with
MS in clinical practice and demonstrates that the MS population
are at greater risk of premature death and certain comorbidities
compared with the non-MS population. The results of this study
extend our understanding of concurrent and/or complicating dis-
eases in MS, providing a context from which clinicians can gain
insight into the impact of MS on patients. This study may alert
clinicians to the importance of increased surveillance of the MS
population to permit targeted earlier interventions that can reduce
the impact of comorbidities on the functional status of patients in
addition to reducing the risk of premature mortality. Finally, this
research may aid in the evaluation and interpretation of adverse
events encountered in the post-approval stage of MS therapies.
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